InnoCan Pharma Corporation (CSE:INNO)
Canada · Delayed Price · Currency is CAD 2.440
+0.090 (3.83%)
Sep 17, 2026, 5:16 PM EST
InnoCan Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 6.4 | 6.69 | 5.01 | 3.89 | 4.95 | 11.05 |
Cash & Short-Term Investments | 6.4 | 6.69 | 5.01 | 3.89 | 4.95 | 11.05 |
Cash Growth | -11.80% | 33.53% | 28.91% | -21.47% | -55.22% | 229.30% |
Accounts Receivable | 0.03 | 0.22 | 0.25 | 0.25 | 0.06 | - |
Other Receivables | 0.97 | 0.72 | 0.29 | 0.42 | 0.18 | 0.17 |
Receivables | 1 | 0.94 | 0.54 | 0.67 | 0.24 | 0.17 |
Inventory | 2.2 | 2.18 | 3.32 | 1.75 | 1.13 | 0.51 |
Prepaid Expenses | 0.12 | 0.07 | 0.07 | 0.34 | 0.45 | 0.72 |
Other Current Assets | 0.57 | 0.55 | 0.22 | 0.17 | 0.1 | 0.08 |
Total Current Assets | 10.28 | 10.44 | 9.15 | 6.8 | 6.88 | 12.52 |
Property, Plant & Equipment | 0.08 | 0.09 | 0.11 | 0.14 | 0.1 | 0.05 |
Total Assets | 10.37 | 10.52 | 9.26 | 6.94 | 6.98 | 12.58 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.36 | 0.24 | 0.19 | 0.11 | 0.1 | 0.05 |
Accrued Expenses | 0.88 | 0.73 | 0.48 | 0.46 | 0.32 | 0.43 |
Current Portion of Leases | - | - | 0.01 | 0.02 | 0.01 | 0 |
Other Current Liabilities | 0.05 | 0.39 | 1.57 | 1.95 | 0.3 | 3.08 |
Total Current Liabilities | 1.96 | 1.36 | 2.24 | 2.54 | 0.73 | 3.56 |
Long-Term Debt | 1 | 0.93 | - | - | - | - |
Long-Term Leases | - | - | - | 0.01 | 0.02 | - |
Total Liabilities | 2.95 | 2.29 | 2.24 | 2.55 | 0.75 | 3.56 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 41.84 | 41.63 | 40.08 | 37.18 | 34.77 | 33.67 |
Retained Earnings | -37.04 | -36.03 | -34.91 | -33.07 | -28.37 | -24.61 |
Total Common Equity | 4.8 | 5.6 | 5.17 | 4.1 | 6.39 | 9.06 |
Minority Interest | 2.61 | 2.64 | 1.86 | 0.28 | -0.17 | -0.04 |
Shareholders' Equity | 7.41 | 8.24 | 7.02 | 4.39 | 6.23 | 9.01 |
Total Liabilities & Equity | 10.37 | 10.52 | 9.26 | 6.94 | 6.98 | 12.58 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.66 | 0.93 | 0.01 | 0.03 | 0.03 | 0 |
Net Cash (Debt) | 4.74 | 5.76 | 5 | 3.85 | 4.91 | 11.05 |
Net Cash Growth | -19.17% | 15.19% | 29.75% | -21.60% | -55.53% | 233.04% |
Net Cash Per Share | 1.05 | 1.29 | 1.16 | 0.97 | 1.28 | 3.20 |
Filing Date Shares Outstanding | 4.5 | 4.5 | 4.48 | 4.32 | 3.87 | 3.82 |
Total Common Shares Outstanding | 4.5 | 4.5 | 4.46 | 4.12 | 3.84 | 3.82 |
Working Capital | 8.33 | 9.08 | 6.91 | 4.26 | 6.15 | 8.96 |
Book Value Per Share | 1.07 | 1.24 | 1.16 | 1.00 | 1.66 | 2.37 |
Tangible Book Value | 4.8 | 5.6 | 5.17 | 4.1 | 6.39 | 9.06 |
Tangible Book Value Per Share | 1.07 | 1.24 | 1.16 | 1.00 | 1.66 | 2.37 |